Clarius OB AI reportedly provides estimates of fetal age, weight and growth intervals based on automated fetal biometry measurements available through handheld ultrasound.
The Food and Drug Administration (FDA) has granted 510(k) clearance for Clarius OB AI, an AI-powered handheld ultrasound tool that may bolster access for use of the technology in monitoring fetal wellbeing.
Trained on over 30,000 fetal ultrasound images, Clarius OB AI automates appropriate caliper placement for the calculation of fetal biometry measurements and enables one to add the measurements to patient electronic medical records through the Clarius app, according to Clarius, the developer of Clarius OB AI.
Carolyn L. Gegor, CNN, MS, FACNM, called the Clarius OB AI tool an “excellent teaching modality” that could help reduce the learning curve with OB ultrasound for those who lack experience with ultrasound scanning.
"When I used Clarius OB AI while teaching OB ultrasound to a group of midwives, I was impressed by the accuracy of cursor placement on multiple scans, from crown rump length to biparietal diameter and femur length," noted Gegor, an ARDMS-certified midwife sonographer. "I found that after using the OB AI model, the students were more able to properly measure structures without the assistance of the AI.”
Clarius noted the Clarius OB AI tool is included with Clarius membership and available in the United States and Canada with the Clarius C3 HD3 handheld ultrasound device.
New Study Examines Short-Term Consistency of Large Language Models in Radiology
November 22nd 2024While GPT-4 demonstrated higher overall accuracy than other large language models in answering ACR Diagnostic in Training Exam multiple-choice questions, researchers noted an eight percent decrease in GPT-4’s accuracy rate from the first month to the third month of the study.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Ultrasound Device Garners FDA De Novo Nod for Kidney Stone Clearance
November 14th 2024Emerging research demonstrated that the Stone Clear device, which facilitates post-lithotripsy clearance of kidney stone fragments, led to a 70 percent lower risk of relapse in comparison to observation in a control group.